Repligen corp stock.

Oct 9, 2023 · With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ... Apr 21, 2020 · However, Repligen stock has ramped up nearly 33% in the aftermath, slightly outperforming even a bullish 30% gain for its medical products peers. Janney analyst Paul Knight expects the company to ... Successfully navigating the dynamic landscape of stock investing requires an understanding of factors like momentum to judge a stock’s price trend. In this article, we take an in-depth look at Repligen Corp (RGEN) to unravel why momentum evaluation plays a crucial role in making savvy investment choices. We also examine how to measure ...The high estimate for the stock was $240.00, while the low estimate was $165.00. The consensus among the 13 polled investment analysts is to buy stock in Repligen Corp. This rating has remained unchanged since August. Repligen Corp is a bioprocessing company that provides products and services to the life sciences industry.

Oct 23, 2023 · Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 41. Comparing Premier Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 12.34% in the past year. Currently, Repligen Corp’s price-earnings ratio is 74.0. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.

Repligen Corp stock has a Value Score of 4, Growth Score of 82 and Momentum Score of 43. Comparing Medtronic PLC and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk …Fundamentals REPLIGEN CORP. DL-,01. Dividend. Dividend yield in %. P/E Ratio. Profit per share. Number of shares. Market capitalization. News about REPLIGEN ...Repligen Corp’s ( RGEN) price is currently down 4.66% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $160.14. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 37.23%.Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. Analysts expect adjusted earnings to reach $2.678 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare DexCom, Inc. and Repligen Corp Stock ...

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments.

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments.

Repligen Corp. SEC filings breakout by MarketWatch. View the RGEN U.S. Securities and Exchange Commission reporting information.Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36.Repligen Corp., which was founded by Alexander G., provides bioprocessing technologies and services utilized in producing biological drugs. ... With institutions owning 91% of its stock, it’s clear that Repligen is attracting some serious attention from experienced and savvy investors who see its potential for growth in the biotech sector ...The stock’s market cap achieved a total value of $6.67 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Repligen Corp. (NASDAQ:RGEN) is 49.48.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.

With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Nov 15, 2023 · On November 14, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $153.79 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 7.92%, and its shares lost 19.47% of their ... UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Feb 28, 2023 · Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. Analysts expect adjusted earnings to reach $2.678 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare DexCom, Inc. and Repligen Corp Stock ... The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...

Nov 23, 2023 · The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN ... Repligen Corp. (NASDAQ:RGEN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in ...

... Stock quotes by finanzen.net · Home · Stocks · Repligen-stock · News for Repligen Repligen. News for Repligen Corp. GlobeNewswire 20d. UPDATE – Repligen ...Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Nov 15, 2023 · On November 14, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $153.79 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 7.92%, and its shares lost 19.47% of their ... Feb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%. We explain indepth Repligen Corp financials and how to pick the best broker to invest Repligen Corp stocks and CFDs with. Comparebrokers.co. Popular. Technology. Zoom (ZM) AMD (AMD) Facebook (FB) Netflix (NFLX) Growing. Apple (AAPL) Tesla (TSLA) Amazon (AMZN) Astrazeneca PLC (AZN) Economy.A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.RGEN Repligen Corp. 161.78 1.57 ( 0.98%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.Sep 18, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ...

A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Oct 31, 2023 · WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for ... Oct 12, 2021. The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop ... Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corporation stock price live 159.46, this page displays NASDAQ RGEN stock exchange data. View the RGEN premarket stock price ahead of the market session or …Repligen Corp stock has a Value Score of 6, Growth Score of 82 and Estimate Revisions Score of 38. Comparing West Pharmaceutical Services Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset …Oct 13, 2023 · Avantor Inc does not currently pay a dividend. Currently, Repligen Corp’s price-earnings ratio is 63.2. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.748 per share for the current fiscal ... See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Dimensional Fund Advisors LP raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 8.2% during the 2nd quarter, HoldingsChannel.com …Repligen Corporation (NasdaqGS:RGEN) completed the acquisition of Bio-Flex Solutions, L.L.C. / Newton T & M Corp for $31.8 million on December 16, 2021. The purchase price of $31.8 million includes $3 million deposited into an escrow against which the Company may make claims for indemnification.WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “ Making an Impact ”, the report highlights …

1 thg 11, 2023 ... While Repligen Corporation ( NASDAQ:RGEN ) might not be the most widely known stock at the moment, it saw a...UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.11 brokers have issued 12-month price targets for Repligen's stock. Their RGEN share price targets range from $165.00 to $210.00. On average, they expect the company's share price to reach $189.55 in the next year. This suggests a possible upside of 19.5% from the stock's current price.Instagram:https://instagram. nysearca xopwayfair net worth10 year municipal bond ratefunded futures Repligen Corp stock has a Value Score of 6, Growth Score of 82 and Estimate Revisions Score of 38. Comparing West Pharmaceutical Services Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset … armtradeis the chinese economy in trouble Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ... peloton financials 305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs.Repligen Q3 Results Top Estimates; Boosts FY23 Earnings Outlook. (RTTNews) - Life sciences company Repligen Corp. (RGEN) announced Tuesday third-quarter net income of $18.17 million or $0.32 per ...